PF 2393296Alternative Names: PF-2393296
Latest Information Update: 28 Apr 2009
At a glance
- Originator Pfizer
- Mechanism of Action Calcium channel antagonists; GABA receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 31 Mar 2009 Discontinued - Phase-I for Pain in USA (PO)
- 28 Feb 2008 Phase-I for Pain in USA (PO)